Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when HQY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsHealthEquity appoints Sanford Health CEO to Board, creating customer relationship
Filed March 30, 2026 · Period ending March 26, 2026 · ~1 min read
Key Changes
-
medium
William Gassen, CEO of Sanford Health, joined HealthEquity's Board effective March 26, expanding the Board to ten members. He will serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee.
Item 5.02 verify on EDGAR → -
medium
Sanford Health paid HealthEquity $123,923 in fiscal 2026 for employee benefits services and expects to pay over $120,000 in fiscal 2027, creating a related party relationship with the new director.
Item 5.02 verify on EDGAR → -
low
Gassen will receive standard non-employee director compensation including retainer fees and annual equity awards under the existing director compensation policy.
Item 5.02 verify on EDGAR →
Summary
HealthEquity expanded its Board of Directors to ten members by appointing William Gassen, the CEO of Sanford Health, effective March 26, 2026. The appointment creates a notable related party relationship: Sanford Health is a HealthEquity customer that paid the company nearly $124,000 last fiscal year for consumer-directed benefits services and is expected to continue as a customer in fiscal 2027. For retail investors, this appointment raises standard governance questions about director independence when a board member leads a customer organization, though the revenue amount appears immaterial relative to HealthEquity's overall business.
Gassen will serve on both the Audit and Risk Committee and the Talent, Compensation and Culture Committee, giving him oversight of financial controls and executive compensation. Watch for proxy disclosures detailing how the Board evaluated Gassen's independence despite the Sanford Health relationship, and whether the customer relationship grows materially in future periods.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
HealthEquity appointed Mr. Gassen to its Board of Directors, disclosed via press release under Regulation FD.
Added in current filing · verify on EDGAR →
A copy of the Company’s press release announcing the appointment of Mr. Gassen to the Board is attached hereto as Exhibit 99.1.
HealthEquity disclosed the appointment of Mr. Gassen to its Board of Directors. The company issued a press release to announce this governance change, furnished under Regulation FD disclosure rules. No additional details about Mr. Gassen's background, committee assignments, or compensation are provided in the 8-K body itself.
Event · Item 9.01 — Financial Statements and Exhibits
HealthEquity filed an 8-K attaching a press release and referencing standard indemnification and director compensation exhibits.
Added in current filing · view on EDGAR →
99.1+ Press release issued by HealthEquity, Inc. on March 30, 2026
The company filed a press release dated March 30, 2026 as Exhibit 99.1. The 8-K does not describe the content of the press release in the body text, so the specific subject matter and materiality cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify